Treatment of Classic Hairy-Cell Leukemia Requiring Therapy When Active Infection Cannot Be Controlled
This protocol addresses one of the most clinically challenging presentations of hairy cell leukemia: a patient who requires antileukemia treatment but has an active infection that cannot first be brought under adequate control.
Clinical Situation
The patient has classic hairy cell leukemia and meets criteria requiring treatment. An active infection is concurrently present. The defining difficulty of this scenario is that the infection cannot be adequately controlled before antileukemia therapy must be considered — a situation that directly shapes the treatment strategy.
Treatment Approach (Partial Overview)
The approach first attempts to bring infection under control before proceeding with standard antileukemia therapy. When that is not achievable, selected alternative agents — chosen specifically because they are not associated with worsening myelosuppression — may be used to improve the absolute neutrophil count and create conditions for more definitive treatment.
The full structured regimen, including specific agent selection, sequencing, and clinical decision points, is available in the complete protocol.
Clinical Goals
Improvement in the absolute neutrophil count and control of the active infection, enabling safe progression to durable antileukemia therapy.
References
DOI: 10.1182/blood-2016-01-689422
- One of the most challenging clinical situations involves the patient with HCL who requires treatment but has an active infection.
- If it is not possible to control the infection and antileukemia therapy is needed, then a decision regarding primary therapy requires the use of either a purine analog or interferon alpha.
- Attempts to control the infection should be pursued before beginning treatment with the purine nucleoside analog.
- If active infection is present, attempts to control infection should be pursued before instituting the purine nucleoside regimen.
- If it is not possible to control infection, alternative therapy with interferon alpha, low-dose pentostatin, or newer agents (eg, vemurafenib) not associated with worsening myelosuppression may be used to improve the absolute neutrophil count in an attempt to control infection before using regular-dose purine analogs to secure a durable response.
View source ↗